Clinical Trials Browser

Phase 2 × Terminated × ascrinvacumab × Clear all

NCT01911273 2015-10-28

A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer

Phase 2 Terminated

3 enrolled 4 charts

Gastrointestinal

Carcinoma, Hepatocellular